CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
type: MedicalStudy
description: Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme
status: UNKNOWN
study design: INTERVENTIONAL
phase: PHASE2
start date: 2007-10
end date: 2011-12
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00562419
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
study subject: Brain and Central Nervous System Tumors
study subject: Recurrent Glioblastoma Multiforme
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: UNKNOWN
keywords: Brain and Central Nervous System Tumors
keywords: Recurrent Glioblastoma Multiforme

AI Analytics
type: Organization